Evidence map›Paper›PMID 37677054›Full record

ArticleCardiovascular research2023

Atrial fibrillation-associated electrical remodelling in human induced pluripotent stem cell-derived atrial cardiomyocytes: a novel pathway for antiarrhythmic therapy development.

Fitzwilliam Seibertz, Tony Rubio, Robin Springer, Fiona Popp, Melanie Ritter, Aiste Liutkute, Lena Bartelt, Lea Stelzer, Fereshteh Haghighi, Jan Pietras and 15 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Optogenetic tachypacing facilitates burst-induced arrhythmia in stem cell-derived human atrial engineered heart tissue.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 5 institutions in 1 country.

Fitzwilliam SeibertzInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.ORCID 0000-0002-8554-5186
Tony RubioInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Robin SpringerInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Fiona PoppInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.ORCID 0009-0001-5248-3273
Melanie RitterInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Aiste LiutkuteInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Lena BarteltInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Lea StelzerInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Fereshteh HaghighiDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.
Jan PietrasDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.
Hendrik WindelDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.
Núria Díaz I PedrosaInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Markus RapediusNanion Technologies GmbH, Munich, Germany.ORCID 0000-0002-9917-9922
Yannic DoeringInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Richard SolanoInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.ORCID 0000-0001-7608-6099
Robin HindmarshDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.
Runzhu ShiDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.
Malte TiburcyInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.
Tobias BruegmannDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.ORCID 0000-0002-6930-9634
Ingo KutschkaDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.ORCID 0000-0002-7358-3513
Katrin Streckfuss-BömekeDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.ORCID 0000-0001-5137-7228
George KensahDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.ORCID 0000-0003-0219-8279
Lukas CyganekDZHK (German Center for Cardiovascular Research), partner site Göttingen, Germany.ORCID 0000-0001-9120-1382
Wolfram H ZimmermannInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.ORCID 0000-0003-1190-4040
Niels VoigtInstitute of Pharmacology and Toxicology, University Medical Center Göttingen, Georg-August University Göttingen, Robert-Koch-Straße 40, 37075 Göttingen, Germany.ORCID 0000-0001-8230-2341
Universitätsmedizin Göttingen · DEGerman Centre for Cardiovascular Research · DEGerman Center for Neurodegenerative Diseases · DENanion (Germany) · DEUniversity of Würzburg · DE

Funding

BMBF 01GM1902DDeutsche Forschungsgemeinschaft DFG, VO 1568/3-1, VO 1568/4-1, IRTG1816 project 12, SFB1002DZHKElse-Kröner-Fresenius-StiftungFondation Leducq 20CVD04German Center for Cardiovascular Research 81X2300189 and 81X4300102Göttingen Promotionskolleg für MedizinstudierendeJacob-Henle-Programm
6 · The paper itself

Abstract

aimsAtrial fibrillation (AF) is associated with tachycardia-induced cellular electrophysiology alterations which promote AF chronification and treatment resistance. Development of novel antiarrhythmic therapies is hampered by the absence of scalable experimental human models that reflect AF-associated electrical remodelling. Therefore, we aimed to assess if AF-associated remodelling of cellular electrophysiology can be simulated in human atrial-like cardiomyocytes derived from induced pluripotent stem cells in the presence of retinoic acid (iPSC-aCM), and atrial-engineered human myocardium (aEHM) under short term (24 h) and chronic (7 days) tachypacing (TP). METHODS AND

resultsFirst, 24-h electrical pacing at 3 Hz was used to investigate whether AF-associated remodelling in iPSC-aCM and aEHM would ensue. Compared to controls (24 h, 1 Hz pacing) TP-stimulated iPSC-aCM presented classical hallmarks of AF-associated remodelling: (i) decreased L-type Ca2+ current (ICa,L) and (ii) impaired activation of acetylcholine-activated inward-rectifier K+ current (IK,ACh). This resulted in action potential shortening and an absent response to the M-receptor agonist carbachol in both iPSC-aCM and aEHM subjected to TP. Accordingly, mRNA expression of the channel-subunit Kir3.4 was reduced. Selective IK,ACh blockade with tertiapin reduced basal inward-rectifier K+ current only in iPSC-aCM subjected to TP, thereby unmasking an agonist-independent constitutively active IK,ACh. To allow for long-term TP, we developed iPSC-aCM and aEHM expressing the light-gated ion-channel f-Chrimson. The same hallmarks of AF-associated remodelling were observed after optical-TP. In addition, continuous TP (7 days) led to (i) increased amplitude of inward-rectifier K+ current (IK1), (ii) hyperpolarization of the resting membrane potential, (iii) increased action potential-amplitude and upstroke velocity as well as (iv) reversibly impaired contractile function in aEHM.

conclusionsClassical hallmarks of AF-associated remodelling were mimicked through TP of iPSC-aCM and aEHM. The use of the ultrafast f-Chrimson depolarizing ion channel allowed us to model the time-dependence of AF-associated remodelling in vitro for the first time. The observation of electrical remodelling with associated reversible contractile dysfunction offers a novel platform for human-centric discovery of antiarrhythmic therapies.

Indexed as

Atrial FibrillationAtrial RemodelingInduced Pluripotent Stem CellsAcetylcholineAction PotentialsAnti-Arrhythmia AgentsHeart AtriaHumansMyocytes, CardiacAcetylcholineAnti-Arrhythmia AgentsAction potentialAtrial fibrillationIon channelOptogeneticsStem cells

Identifiers

PMID37677054
PMCPMC10730244
OpenAlexW4386519231

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.